NYSE - Delayed Quote USD

Novartis AG (NVS)

92.57

-0.51

(-0.55%)

At close: April 18 at 4:00 PM EDT

92.82

+0.25

(+0.27%)

Pre-Market: 5:53 AM EDT

US FDA mandates label updates on CAR-T cancer therapies

The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of T-cell blood cancer in patients who use these therapies. The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medication guide. In January, the FDA asked a host of drugmakers including Gilead Sciences, Johnson & Johnson and Novartis to add a boxed warning to their CAR-T cancer therapies, as it received reports of patients developing a type of T-cell blood cancer after being treated with them.

Reuters 11 hours ago

NVS
-0.55%
JNJ

GILD
-1.15%
Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS

Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks 20 hours ago

NVS
-0.55%
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years

These income stocks look like good options at current levels.

Motley Fool yesterday

CELG-RT

NVS
-0.55%
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open-label extension study1Similar efficacy outcomes were demonstrated in a separate analysis of continuous Kesimpta treatment for up to six years in the overall ALITHIOS study population2 Switch from teriflunomide to Kesimpta resulted in significant improvements across several efficacy o

GlobeNewswire 2 days ago

NVS
-0.55%
NVSEF
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug

Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.

Zacks 2 days ago

NVS
-0.55%
CALTX.ST
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)

APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide2; complement activation is a key driver of glomerular inflammation in IgAN3,4There is a need for effective, targeted therapies for IgAN2,5; up to 30% of patients with persistent proteinuria (≥1 g/day) may progress to kidney failure

GlobeNewswire 3 days ago

NVS
-0.55%
NVSEF
Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining.

Antitrust lawsuits have declined since the pandemic despite a high-profile push by Washington to limit the concentration of power in key industries.

Yahoo Finance 4 days ago

COST

GOOG

META
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.

Zacks 6 days ago

NVS
-0.55%
ARVN

MOR.DE
Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

Biotech stocks heated up Thursday as Novartis scooped up a licensing pact with Arvinas and Janux was said to be exploring strategic options.

Investor's Business Daily 7 days ago

ARVN

NVS
-0.55%
JANX
Novartis (NVS) to Undertake Job Cuts in Development Department

Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.

Zacks 7 days ago

NVS
-0.55%
MOR.DE
UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion

Swiss drugmaker Novartis AG has entered into a licensing deal worth up to $1.01 billion with Arvinas to gain access to the U.S. biotech firm's experimental prostate cancer drug, Arvinas said on Thursday. Shares of Connecticut-based Arvinas rose more than 6% to $39 in premarket trade. The pact adds to Novartis' pursuit of cancer treatments after it launched a tender offer on Thursday to acquire German cancer drugmaker MorphoSys for an aggregate 2.7 billion euros ($2.9 billion).

Reuters 7 days ago

ARVN

NVS
-0.55%
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties – – Novartis to be responsible for worldwide clinical development and commercialization of ARV-766 – – Partnership expected to accelerate and broaden the development of ARV-766 as a potential first-in-class treatmen

GlobeNewswire 7 days ago

NVS
-0.55%
NVSEF

ARVN
UPDATE 3-Novartis begins tender offer for cancer-focused MorphoSys

Novartis said on Thursday it has launched a tender offer to acquire MorphoSys , a German developer of cancer treatments, for an aggregate 2.7 billion euros ($2.9 billion). Reuters reported in February that Swiss drugmaker Novartis would buy MorphoSys, which had an equity market value of around 1.6 billion euros before the offer was announced. The Swiss drugmaker said its cash offer price of 68 euros per MorphoSys share corresponds to a premium of 142% on the volume-weighted average price during the last three months, as of the unaffected closing price on Jan. 25.

Reuters 8 days ago

NVS
-0.55%
MOR.DE
Novartis tender offer for MorphoSys AG commences

Basel, April 11, 2024 – Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG (“MorphoSys”), including all shares represented by MorphoSys American Depositary Shares (the “Offer”), for an offer price of EUR 68.00 per share in cash. The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months, as of the unaffected January 2

GlobeNewswire 8 days ago

NVS
-0.55%
NVSEF
Novartis pauses enrollment in some Kisqali trials to fix manufacturing

The company said the pause is necessary to meet regulatory limits on nitrosamine, but added it will not affect commercial supply nor regulatory review of the drug in early breast cancer.

BioPharma Dive 8 days ago

NVS
-0.55%
Novartis to cut 680 jobs in product development

Novartis is to cut up to 680 jobs in its development organisation, which helps bring its drugs to market, the Swiss pharmaceuticals company said on Tuesday. Around 440 jobs will go in Switzerland and up to 240 in the United States over the next two to three years, the Basel-based company said. The job eliminations are separate from a restructuring programme which could lead up to 8,000 of Novartis's 78,000 global workforce being cut, it said.

Reuters 9 days ago

NVS
-0.55%
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm while maintaining adherence to statin treatment1Results from usual care arm reinforce

GlobeNewswire 12 days ago

NVS
-0.55%
NVSEF
Novartis (NVS) Stock Sinks As Market Gains: Here's Why

In the latest trading session, Novartis (NVS) closed at $95.79, marking a -1.14% move from the previous day.

Zacks 13 days ago

NVS
-0.55%
Novartis (NVS) Declines More Than Market: Some Information for Investors

In the most recent trading session, Novartis (NVS) closed at $94.41, indicating a -1.52% shift from the previous trading day.

Zacks 16 days ago

NVS
-0.55%
25 Countries with Highest Malaria Death Rates

In this article, we will be taking a look at the 25 countries with highest malaria death rates. If you do not want to learn about the global malaria diagnostics market, head straight to the 5 Countries with Highest Malaria Death Rates. Global Malaria Diagnostics Market and Fatalities Overview The global malaria diagnostics market is […]

Insider Monkey 18 days ago

NVS
-0.55%
MMM-WI

Performance Overview

Return	NVS	MSCI WORLD
YTD	-4.82%	+3.28%
1-Year	-1.25%	+15.42%
3-Year	+18.70%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novartis AG (NVS)

US FDA mandates label updates on CAR-T cancer therapies

Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS

2 High-Yield Dividend Stocks to Buy and Hold for 10 Years

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis

Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)

Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining.

Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

Novartis (NVS) to Undertake Job Cuts in Development Department

UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

UPDATE 3-Novartis begins tender offer for cancer-focused MorphoSys

Novartis tender offer for MorphoSys AG commences

Novartis pauses enrollment in some Kisqali trials to fix manufacturing

Novartis to cut 680 jobs in product development

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

Novartis (NVS) Stock Sinks As Market Gains: Here's Why

Novartis (NVS) Declines More Than Market: Some Information for Investors

25 Countries with Highest Malaria Death Rates

Performance Overview